Trial Summary:

The aim of these MoST substudies is to assess the clinical activity of combination of palbociclib and avelumab after initial priming with palbociclib in patients with advanced cancer with eligible mutations of the following:

1. Gain-of function mutations in CDK4 and CCND1-3
2. CDKN2A deletion or loss-of-function mutations

Supported By:

Eligibility:

Adults with tumours expressing amplified D-type cyclins or CDK4/6 or inactivation of CDKN2A. Group 1: Gain-of-function mutation in CDK4 and CCND1-3 OR Group 2: CDKN2A deletion or loss-of-function mutations

Registration ID:

ACTRN12620000568910

Participation:

National

Status:

In follow-up

Activation Date:

29/03/2021

Chairs:

Prof David Thomas

Contact:

most.study@sydney.edu.au